Study of First Affordable and Rapid Test for Beta Thalassemia Performs at 99% Accuracy in Diagnosing the Blood Disorder
05 févr. 2024 08h00 HE
|
Hemex Health
A clinical study demonstrated high accuracy for Hemex Health's beta thalassemia test. It is the only beta thal test for point of care.
Sickle Cell Warrior Program from The National Marrow Donor Program® (NMDP)/Be The Match® Expands Access to Bone Marrow Transplant as a Curative Treatment
31 août 2023 09h00 HE
|
Be The Match
During Sickle Cell Awareness Month, NMPD/Be The Match reminds individuals to visit SickleCellConnect.com to access essential resources, learn more about Sickle Cell Disease, and join the Be The Match...
Be The Match® Celebrates One Thousand “Get in the Game” Life-Saving Donors!
06 juin 2023 08h00 HE
|
Be The Match
MINNEAPOLIS, June 06, 2023 (GLOBE NEWSWIRE) -- Be The Match®, a global leader working to save lives through cellular therapy, today celebrates 1,000 blood stem cell or marrow donors through the “Get...
Pain Intensity in Sickle Cell Disease
14 nov. 2022 10h00 HE
|
Experimental Biology and Medicine
WASHINGTON, Nov. 14, 2022 (GLOBE NEWSWIRE) -- A recently published article in Experimental Biology and Medicine (Volume 247, Issue 17, September, 2022) improves our understanding of pain phenotypes...
Hemex Health announces breakthrough measurement capability for clinicians monitoring sickle cell disease therapy
08 mai 2022 06h00 HE
|
Hemex Health
PORTLAND, Ore. and MUMBAI, India, May 08, 2022 (GLOBE NEWSWIRE) -- Hemex Health, a Portland, Oregon-based health-tech startup, announced a significant enhancement to their Gazelle™ Hb Variant test,...
Sickle Cell Consortium Hosts 6th Annual Leadership Summit - Advocacy & Capacity-Building in the Digital Age
25 avr. 2022 08h00 HE
|
Sickle Cell Consortium
ATLANTA, April 25, 2022 (GLOBE NEWSWIRE) -- The Sickle Cell Consortium hosts the 6th Annual Leadership Summit and General Assembly of Patients, Caregivers, and Community-Based Organizations (CBOs)...
Imara Announces Results of Interim Analyses of Tovinontrine (IMR-687) Phase 2b Clinical Trials in Sickle Cell Disease and Beta-Thalassemia
05 avr. 2022 06h45 HE
|
Imara, Inc.
Interim results in Ardent trial for sickle cell disease showed no significant difference in median annualized rate of vaso-occlusive crises in high-dose group versus placebo in an intent-to-treat...
Imara Reports Full Year 2021 Financial Results and Business Highlights
15 mars 2022 07h00 HE
|
Imara, Inc.
Completed enrollment in Phase 2b sickle cell disease and beta-thalassemia trials with tovinontrine (IMR-687); expect to report both interim datasets in first week of April 2022 Changed primary...
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
08 mars 2022 07h00 HE
|
Imara, Inc.
BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 07h00 HE
|
Imara, Inc.
BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...